Atherogenic lipid profiles in rheumatoid arthritis

New Zealand Medical Journal

Volumn 119, Issue 1240, 2006, Pages

  White, Douglas ^a   Fayez, Sayed ^a   Doube, Alan ^a  

^a WAIKATO HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; GLUCOCORTICOID; LIPID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DIET RESTRICTION; DISEASE ACTIVITY; DISEASE CONTROL; DYSLIPIDEMIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; INFLAMMATION; METABOLISM; MIDDLE AGED; REFERENCE VALUE;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 33747733500     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 1999;26:1701-4.
2. Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med. 2002; 113:188-93.
3. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-45.
4. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:842-5.
5. The New Zealand Guidelines Group. Evidence-based best practice guideline: The assessment and management of cardiovascular risk. Wellington: NZGG; 2003. URL: http://www.nzgg.org.nz/guidelines/dsp guideline popup.cfm?guidelineID=35 Accessed August 2006.
6. Wolfe F. Comparative usefulness of C-reactivc protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol. 1997:1477-85.
7. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol. 2004;31:1746-53.
8. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-9.
9. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study, Lancet. 2002;359:1173-7.
10. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363:2015-21.